A study of targeted radiation for PSMA-positive gliomas
Treatments studied
Part of Cancer clinical trials.
This early-phase trial tests a radioactive drug called 177Lu-PSMA-617 for people with certain types of brain tumors (gliomas) that have a specific marker (PSMA). The drug targets and delivers radiation to the tumor cells. It may be an option if standard treatments have been completed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of brain tumor called a glioma that is IDH-wildtype (not IDH-mutated) and shows PSMA on a lab test of your tumor sample.
- You need to have finished standard treatments like surgery (if possible) and radiation therapy for your glioma.
- If you take dexamethasone (a steroid), your dose must be 4 mg or less per day for at least 5 days before starting the study drug.
- Your kidney, liver, and blood counts must be within certain limits (checked by blood tests).
- You cannot have received bevacizumab (Avastin) as part of your initial glioma treatment, or have certain other medical conditions like active infections or severe liver disease.
- You must be 18 or older, have a life expectancy of at least 12 weeks, and be willing to use reliable birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an experimental radioactive drug called PSMA-617 to standard radiation and hormone therapy helps men with high-risk prostate cancer that hasn't spread beyond the pelvis. The radioactive drug targets cancer cells specifically.
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
This trial tests a flexible dosing schedule of a targeted radiation drug (Lu-PSMA) for men with metastatic prostate cancer that has stopped responding to hormone therapy and chemotherapy. It aims to see if adjusting the treatment schedule can improve outcomes while reducing side effects.
This study tests a combination of focused radiation (SBRT) and a targeted radioactive drug (Lutetium PSMA) for men with prostate cancer that has spread to nearby lymph nodes or has high-risk features but has not yet reached distant organs. The goal is to see if this approach is safe and effective.
This trial tests a radioactive treatment called 177Lu-PSMA-617 for advanced liver cancer that has not responded to first-line immunotherapy. You need a PSMA-PET scan first to see if your cancer absorbs the treatment.
This early-phase study tests a cancer medicine that uses radiation to target prostate cancer cells that carry a specific marker (PSMA). It may help people whose metastatic prostate cancer has stopped responding to hormone therapy and/or chemotherapy.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.